Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2023-12-29 00:00:00 ET · period of report 2023-12-27 · accession 0000950170-23-073837 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-29 | 2023-12-27 | AMLX | Olinger Margaret | Chief Commercial Off | M - OptEx | $0.37 | +25.0K | 276.1K | +10% | +$9,250 |
| D | 2023-12-29 | 2023-12-27 | AMLX | Olinger Margaret | Chief Commercial Off | M - OptEx | $0.00 | -25.0K | 44.6K | -36% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-27 | M | A | 25,000 | $0.37 | 276,108 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-12-27 | M | D | 25,000 | $0.00 | 44,577 | D | $0.37 · — to 2029-05-13 | 25,000 Common Stock | (F1) The shares subject to the option are fully vested and exercisable. |